实用临床医药杂志Issue(15)：70-72,3.DOI:10.7619/jcmp.201415021
重组人血管内皮抑制素在晚期前列腺癌患者中的应用
Applicable exploration of recombinant human endostatin on patientswith advanced prostatic carcinoma
摘要
Abstract
Objective To explore the clinical efficacy of long-term application of recombi-nant human endostatin on patients with advanced prostatic carcinoma.Methods Twenty-eight pa-tients with prostatic carcinoma were divided into control group (10 cases)treated with endocrine therapy and radiotherapy and experimental group (18 cases)added with recombinant human endo-statin.Serum total prostate specific antigen (TPSA)and free prostate specific antigen (FPSA)lev-els were detected and adverse responses were observed.Results FPSA and TPSA levels decreased evidently in both groups after treatment (P <0.01),and were obviously lower in experimental group than in control group 3,6,12 and 28 months after treatment (P <0.01).Additionally, their curve charts showed that their levels in each time point was lower in experimental group than in control group.The number of patients with myelosuppression in degrees Ⅱ and Ⅲ was markedly higher in experimental group than in control group (P <0.01),but there were no significant differ-ences in those with coagulation disorders and gastrointestinal responses (P >0.05).Liver function examination indicated that aspartate transaminase (AST)and alanine transaminase (ALT)had slight increase and were improved after liver-protection therapies,which had no significant differ-ences between two groups (P >0.05).Conclusion Combined application with recombinant human endostatin has better clinical efficacy than single utilization of endocrine therapy and radiotherapy on patients with advanced prostatic carcinoma,in which the myolesuppression is the primary adverse response.关键词
重组人血管内皮抑制素/前列腺癌/血清总前列腺特异性抗原/游离前列腺特异性抗原Key words
recombinant human endostatin/prostatic carcinoma/serum total prostate specific antigen/free prostate specific antigen分类
医药卫生引用本文复制引用
黄国福,冷晓玲..重组人血管内皮抑制素在晚期前列腺癌患者中的应用[J].实用临床医药杂志,2014,(15):70-72,3.基金项目
中国高校医学期刊临床专项资金 （）
